• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » acute myeloid leukemia

Articles Tagged with ''acute myeloid leukemia''

Drug R&D concept image.
Cancer

Auron Therapeutics nominates first candidate for solid and hematologic cancers

Feb. 9, 2024
Auron Therapeutics Inc. has nominated its first development candidate, AUTX-703, which is being developed for the treatment of patients with small-cell lung cancer, neuroendocrine prostate cancer and acute myeloid leukemia.
Read More
Cancer

BD1-selective BET inhibitor exhibits strong antileukemic activity

Feb. 8, 2024
The bromodomain and extraterminal domain (BET) family of proteins are involved in cell cycle regulation and for this reason are considered therapeutic targets in cancer therapeutics.
Read More

Gilead dropping work on anti-CD47 antibody magrolimab

Feb. 7, 2024
By Jennifer Boggs
Gilead Sciences Inc. has officially discontinued work on anti-CD47 antibody magrolimab in hematologic cancers, nearly four years after shelling out $4.9 billion to acquire its developer, Forty Seven Inc. The company announced in its full-year 2023 earnings Feb. 6 call that the phase III Enhance-3 study testing magrolimab as a first-line treatment in unfit acute myeloid leukemia patients was discontinued following a futility analysis and higher incidence of grade 5 adverse events.
Read More
Cancer

Discovery of a potent METTL3-METTL14 complex PROTAC degrader with antileukemic potential

Feb. 5, 2024
The m6A methyltransferase complex is the main catalyzer of N6-methyladenosine (m6A) methylation, the most prevalent RNA modification.
Read More
Cancer

Characterization of novel CDK8 inhibitor for acute myeloid leukemia described

Feb. 5, 2024
Acute myeloid leukemia (AML) presents high recurrence and low survival rates due to drug resistance and different gene mutations that contribute to the difficulty of being cured. Cyclin-dependent kinase 8 (CDK8) is a key oncogenic driver in AML and thus considered a therapeutic target worth exploring.
Read More
Cancer cells under magnifying glass
Cancer

Casinvent Pharma raises financing to advance CK1 inhibitors for solid and hematologic cancers

Jan. 31, 2024
Casinvent Pharma a.s., a spin-off from Masaryk University, has closed a pre-series A funding round, raising a total of €1.6 million (US$1.7 million).
Read More
Acute myeloid leukemia
Cancer

Novel FLT3 PROTAC degrader active in leukemia models

Jan. 24, 2024
One-third of patients with acute myeloid leukemia (AML) present mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. Several first- and next-generation FLT3 inhibitors are currently being used in AML management, but there is a need for new options able to achieve complete and sustained FLT3 signaling suppression.
Read More
Cancer

PI3K and HDAC dual inhibitors show antiproliferative effect in AML models

Jan. 23, 2024
Simultaneous inhibition of the phosphoinositide 3-kinase (PI3K) signaling pathway and histone deacetylase (HDAC) provides synergistic efficacy in the treatment of hematological malignancies.
Read More
Cancer

Combination of TAK-981 and 5-azacytidine shows efficacy in acute myeloid leukemia models

Jan. 17, 2024
SUMOylation is a post-translational modification implicated in DNA damage repair that has been linked to the lack of efficacy of some therapies commonly used for the treatment of leukemia.
Read More
Cancer

TMIGD2 inhibition reduces leukemia burden in AML

Jan. 10, 2024
Poor-to-moderate responses to antileukemic therapies in acute myeloid leukemia (AML) still remain a major challenge.
Read More
Previous 1 2 … 6 7 8 9 10 11 12 13 14 … 24 25 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe